Advertisement

Measles pp 129-162 | Cite as

Reverse Genetics of Measles Virus and Resulting Multivalent Recombinant Vaccines: Applications of Recombinant Measles Viruses

  • M. A. BilleterEmail author
  • H. Y. Naim
  • S. A. Udem
Chapter
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 329)

An overview is given on the development of technologies to allow reverse genetics of RNA viruses, i.e., the rescue of viruses from cDNA, with emphasis on nonsegmented negative-strand RNA viruses ( Mononegavirales ), as exemplified for measles virus (MV). Primarily, these technologies allowed site-directed mutagenesis, enabling important insights into a variety of aspects of the biology of these viruses. Concomitantly, foreign coding sequences were inserted to (a) allow localization of virus replication in vivo through marker gene expression, (b) develop candidate multivalent vaccines against measles and other pathogens, and (c) create candidate oncolytic viruses. The vector use of these viruses was experimentally encouraged by the pronounced genetic stability of the recombinants unexpected for RNA viruses, and by the high load of insertable genetic material, in excess of 6 kb. The known assets, such as the small genome size of the vector in comparison to DNA viruses proposed as vectors, the extensive clinical experience of attenuated MV as vaccine with a proven record of high safety and efficacy, and the low production cost per vaccination dose are thus favorably complemented.

Keywords

Newcastle Disease Virus Measle Virus Chloramphenicol Acetyl Transferase Helper Virus Venezuelan Equine Encephalitis Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Andino R, Silvera D, Suggett SD, Achacoso PL, Miller CJ, Baltimore D, Feinberg MB (1994) Engineering poliovirus as a vaccine vector for the expression of diverse antigens. Science 265:1448–1451PubMedGoogle Scholar
  2. Arroyo J, Miller C, Catalan J, Myers GA, Ratterree MS, Trent DW, Monath TP (2004) ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immuno- genicity, and efficacy. J Virol 78:12497–12507PubMedGoogle Scholar
  3. Atkins GJ, Sheahan BJ, Liljestrom P (1996) Manipulation of the Semliki Forest virus genome and its potential for vaccine construction. Mol Biotechnol 5:33–38PubMedGoogle Scholar
  4. Bailly JE, McAuliffe JM, Durbin AP, Elkins WR, Collins PL, Murphy BR (2000) A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates. J Virol 74:3188–3195PubMedGoogle Scholar
  5. Baron MD, Barrett T (1997) Rescue of rinderpest virus from cloned cDNA. J Virol 71:1265–1271PubMedGoogle Scholar
  6. Bass BL, Weintraub H, Cattaneo R, Billeter MA (1989) Biased hypermutation of viral RNA genomes could be due to unwinding/modification of double-stranded RNA. Cell 56:331PubMedGoogle Scholar
  7. Bennett J V, Fernandez de Castro J, Valdespino-Gomez JL, Garcia-Garcia Mde L, Islas-Romero R, Echaniz-Aviles G, Jimenez-Corona A, Sepulveda-Amor J (2002) Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren. Bull World Health Organ 80:806–812PubMedGoogle Scholar
  8. Bergman I, Griffin JA, Gao Y, Whitaker-Dowling P (2007) Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu. Int J Cancer 121:425–430PubMedGoogle Scholar
  9. Bluming AZ, Ziegler JL (1971) Regression of Burkitt's lymphoma in association with measles infection. Lancet 2:105–106PubMedGoogle Scholar
  10. Brandler S, Tangy F (2007) Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines. Comp Immunol Microbiol Infect Dis 31:271–291PubMedGoogle Scholar
  11. Brandler S, Brown N, Ermak TH, Mitchell F, Parsons M, Zhang Z, Lang J, Monath TP, Guirakhoo F (2005) Replication of chimeric yellow fever virus-dengue serotype 1–4 virus vaccine strains in dendritic and hepatic cells. Am J Trop Med Hyg 72:74–81PubMedGoogle Scholar
  12. Brandler S, Lucas-Hourani M, Moris A, Frenkiel MP, Combredet C, Fevrier M, Bedouelle H, Schwartz O, Despres P, Tangy F (2007) Pediatric measles vaccine expressing a Dengue antigen induces durable serotype-specific neutralizing antibodies to Dengue virus. PLoS Negl Trop Dis 1:e96PubMedGoogle Scholar
  13. Brandsma JL, Shylankevich M, Su Y, Roberts A, Rose JK, Zelterman D, Buonocore L (2007) Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus. J Virol 81:5749–5758PubMedGoogle Scholar
  14. Brave A, Ljungberg K, Wahren B, Liu MA (2007) Vaccine delivery methods using viral vectors. Mol Pharm 4:18–32PubMedGoogle Scholar
  15. Buchholz UJ, Finke S, Conzelmann KK (1999) Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol 73:251–259PubMedGoogle Scholar
  16. Calain P, Roux L (1993) The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol 67:4822–4830PubMedGoogle Scholar
  17. Cattaneo R, Billeter MA (1992) Mutations and A/I hypermutations in measles virus persistent infections. Curr Top Microbiol Immunol 176:63–74PubMedGoogle Scholar
  18. Cattaneo R, Schmid A, Eschle D, Baczko K, ter Meulen V, Billeter MA (1988) Biased hypermuta- tion and other genetic changes in defective measles viruses in human brain infections. Cell 55:255–265PubMedGoogle Scholar
  19. Cattaneo R, Kaelin K, Baczko K, Billeter MA (1989a) Measles virus editing provides an additional cysteine-rich protein. Cell 56:759–764Google Scholar
  20. Cattaneo R, Schmid A, Spielhofer P, Kaelin K, Baczko K, ter Meulen V, Pardowitz J, Flanagan S, Rima BK, Udem SA et al (1989b) Mutated and hypermutated genes of persistent measles viruses which caused lethal human brain diseases. Virology 173:415–425Google Scholar
  21. Clarke DK, Sidhu MS, Johnson JE, Udem SA (2000) Rescue of mumps virus from cDNA. J Virol 74:4831–4838PubMedGoogle Scholar
  22. Clarke DK, Cooper D, Egan MA, Hendry RM, Parks CL, Udem SA (2006) Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector. Springer Semin Immunopathol 28:239–253PubMedGoogle Scholar
  23. Collins PL, Mink MA, Stec DS (1991) Rescue of synthetic analogs of respiratory syncytial virus genomic RNA and effect of truncations and mutations on the expression of a foreign reporter gene. Proc Natl Acad Sci U S A 88:9663–9667PubMedGoogle Scholar
  24. Collins PL, Mink MA, Hill MG 3rd, Camargo E, Grosfeld H, Stec DS (1993) Rescue of a 7502-nucleotide (49.3% of full-length) synthetic analog of respiratory syncytial virus genomic RNA. Virology 195:252–256PubMedGoogle Scholar
  25. Collins PL, Hill MG, Camargo E, Grosfeld H, Chanock RM, Murphy BR (1995) Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci U S A 92:11563–11567PubMedGoogle Scholar
  26. Combredet C, Labrousse V, Mollet L, Lorin C, Delebecque F, Hurtrel B, McClure H, Feinberg MB, Brahic M, Tangy F (2003) A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol 77:11546–11554PubMedGoogle Scholar
  27. Conzelmann KK, Schnell M (1994) Rescue of synthetic genomic RNA analogs of rabies virus by plasmid-encoded proteins. J Virol 68:713–719PubMedGoogle Scholar
  28. Cooper D, Wright KJ, Calderon PC, Guo M, Nasar F, Johnson JE, Coleman JW, Lee M, Kotash C, Yurgelonis I, Natuk RJ, Hendry RM, Udem SA, Clarke DK (2008) Attenuation of recom-binant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogeni-city in mice. J Virol 82:207–219PubMedGoogle Scholar
  29. del Valle JR, Devaux P, Hodge G, Wegner NJ, McChesney MB, Cattaneo R (2007) A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. J Virol 81:10597–10605PubMedGoogle Scholar
  30. Delenda C, Taylor G, Hausmann S, Garcin D, Kolakofsky D (1998) Sendai viruses with altered P, V, and W protein expression. Virology 242:327–337PubMedGoogle Scholar
  31. Despres P, Combredet C, Frenkiel MP, Lorin C, Brahic M, Tangy F (2005) Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis 191:207–214PubMedGoogle Scholar
  32. Devaux P, Hodge G, McChesney MB, Cattaneo R (2008) Attenuation of V- or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys. J Virol 82:5359–5367PubMedGoogle Scholar
  33. Diaz RM, Galivo F, Kottke T, Wongthida P, Qiao J, Thompson J, Valdes M, Barber G, Vile RG (2007) Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 67:2840–2848PubMedGoogle Scholar
  34. DiNapoli JM, Kotelkin A, Yang L, Elankumaran S, Murphy BR, Samal SK, Collins PL, Bukreyev A (2007) Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intra-nasal immunization against emerging pathogens. Proc Natl Acad Sci U S A 104:9788–9793PubMedGoogle Scholar
  35. Domingo E, Sabo D, Taniguchi T, Weissmann C (1978) Nucleotide sequence heterogeneity of an RNA phage population. Cell 13:735–744PubMedGoogle Scholar
  36. Duprex WP, Duffy I, McQuaid S, Hamill L, Cosby SL, Billeter MA, Schneider-Schaulies J, ter Meulen V, Rima BK (1999a) The H gene of rodent brain-adapted measles virus confers neu-rovirulence to the Edmonston vaccine strain. J Virol 73:6916–6922Google Scholar
  37. Duprex WP, McQuaid S, Hangartner L, Billeter MA, Rima BK (1999b) Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J Virol 73:9568–9575Google Scholar
  38. Duprex WP, Collins FM, Rima BK (2002) Modulating the function of the measles virus RNA-dependent RNA polymerase by insertion of green fluorescent protein into the open reading frame. J Virol 76:7322–7328PubMedGoogle Scholar
  39. Durbin AP, Hall SL, Siew JW, Whitehead SS, Collins PL, Murphy BR (1997) Recovery of infectious human parainfluenza virus type 3 from cDNA. Virology 235:323–332PubMedGoogle Scholar
  40. Enami M, Luytjes W, Krystal M, Palese P (1990) Introduction of site-specific mutations into the genome of influenza virus. Proc Natl Acad Sci U S A 87:3802–3805PubMedGoogle Scholar
  41. Erlenhofer C, Duprex WP, Rima BK, ter Meulen V, Schneider-Schaulies J (2002) Analysis of receptor (CD46, CD150) usage by measles virus. J Gen Virol 83:1431–1436PubMedGoogle Scholar
  42. Escoffier C, Manie S, Vincent S, Muller CP, Billeter M, Gerlier D (1999) Nonstructural C protein is required for efficient measles virus replication in human peripheral blood cells. J Virol 73:1695–1698PubMedGoogle Scholar
  43. Estevez C, King D, Seal B, Yu Q (2007) Evaluation of Newcastle disease virus chimeras expressing the Hemagglutinin-Neuraminidase protein of velogenic strains in the context of a mes-ogenic recombinant virus backbone. Virus Res 129:182–190PubMedGoogle Scholar
  44. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A (1999) Rescue of influenza A virus from recombinant DNA. J Virol 73:9679–9682PubMedGoogle Scholar
  45. Garcin D, Pelet T, Calain P, Roux L, Curran J, Kolakofsky D (1995) A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: generation of a novel copy-back nondefective interfering virus. EMBO J 14:6087–6094PubMedGoogle Scholar
  46. Garcin D, Latorre P, Kolakofsky D (1999) Sendai virus C proteins counteract the interferon-medi-ated induction of an antiviral state. J Virol 73:6559–6565PubMedGoogle Scholar
  47. Garcin D, Curran J, Kolakofsky D (2000) Sendai virus C proteins must interact directly with cellular components to interfere with interferon action. J Virol 74:8823–8830PubMedGoogle Scholar
  48. Garcin D, Curran J, Itoh M, Kolakofsky D (2001) Longer and shorter forms of Sendai virus C proteins play different roles in modulating the cellular antiviral response. J Virol 75:6800–6807PubMedGoogle Scholar
  49. Garcin D, Marq JB, Strahle L, le Mercier P, Kolakofsky D (2002) All four Sendai Virus C proteins bind Stat1, but only the larger forms also induce its mono-ubiquitination and degradation. Virology 295:256–265PubMedGoogle Scholar
  50. Ge J, Deng G, Wen Z, Tian G, Wang Y, Shi J, Wang X, Li Y, Hu S, Jiang Y, Yang C, Yu K, Bu Z, Chen H (2007) Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J Virol 81:150–158PubMedGoogle Scholar
  51. Hangartner L (1997) Development of measles virus as a vector: expression of green fluorescent protein from different loci. Master's thesis, University of Zurich, Zurich, SwitzerlandGoogle Scholar
  52. He B, Paterson RG, Ward CD, Lamb RA (1997) Recovery of infectious SV5 from cloned DNA and expression of a foreign gene. Virology 237:249–260PubMedGoogle Scholar
  53. Hoffman MA, Banerjee AK (1997) An infectious clone of human parainfluenza virus type 3. J Virol 71:4272–4277PubMedGoogle Scholar
  54. Hoffman SJ, Polack FP, Hauer DA, Singh M, Billeter MA, Adams RJ, Griffin DE (2003) Vaccination of rhesus macaques with a recombinant measles virus expressing interleukin-12 alters humoral and cellular immune responses. J Infect Dis 188:1553–1561PubMedGoogle Scholar
  55. Huber M, Cattaneo R, Spielhofer P, Orvell C, Norrby E, Messerli M, Perriard JC, Billeter MA (1991) Measles virus phosphoprotein retains the nucleocapsid protein in the cytoplasm. Virology 185:299–308PubMedGoogle Scholar
  56. Janke M, Peeters B, de Leeuw O, Moorman R, Arnold A, Fournier P, Schirrmacher V (2007) Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther 14:1639–1649PubMedGoogle Scholar
  57. Johnson JE, Nasar F, Coleman JW, Price RE, Javadian A, Draper K, Lee M, Reilly PA, Clarke DK, Hendry RM, Udem SA (2007) Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 360:36–49PubMedGoogle Scholar
  58. Karron R, Collins P (2007) Parainflueza viruses. In: Knipe D, Howley P (eds) Fields virology, vol. 1. Lippincott Williams, Wilkins, Philadelphia, pp 1497–1526Google Scholar
  59. Kato A, Sakai Y, Shioda T, Kondo T, Nakanishi M, Nagai Y (1996) Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. Genes Cells 1:569–579PubMedGoogle Scholar
  60. Klenerman P, Hengartner H, Zinkernagel RM (1997) A non-retroviral RNA virus persists in DNA form. Nature 390:298–301PubMedGoogle Scholar
  61. Kobune F, Sakata H, Sugiura A (1990) Marmoset lymphoblastoid cells as a sensitive host for isolation of measles virus. J Virol 64:700–705PubMedGoogle Scholar
  62. Lamb R, Parks G (2007) Paramyxoviridae: the viruses and their replication. In: Knipe D, Howley P (eds) Fields virology, vol 1. Lippincott Williams Wilkins, Philadelphia, pp 1449–1496Google Scholar
  63. Lawson ND, Stillman EA, Whitt MA, Rose JK (1995) Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A 92:4477–4481PubMedGoogle Scholar
  64. Li S, Locke E, Bruder J, Clarke D, Doolan DL, Havenga MJ, Hill AV, Liljestrom P, Monath TP, Naim HY, Ockenhouse C, Tang DC, Van Kampen KR, Viret JF, Zavala F, Dubovsky F (2007) Viral vectors for malaria vaccine development. Vaccine 25:2567–2574PubMedGoogle Scholar
  65. Liniger M, Zuniga A, Tamin A, Azzouz-Morin TN, Knuchel M, Marti RR, Wiegand M, Weibel S, Kelvin D, Rota PA, Naim HY (2008) Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses. Vaccine 26:2164–2174PubMedGoogle Scholar
  66. Lorence RM, Roberts MS, O'Neil JD, Groene WS, Miller JA, Mueller SN, Bamat MK (2007) Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr Cancer Drug Targets 7:157–167PubMedGoogle Scholar
  67. Lorin C, Mollet L, Delebecque F, Combredet C, Hurtrel B, Charneau P, Brahic M, Tangy F (2004) A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J Virol 78:146–157PubMedGoogle Scholar
  68. Luytjes W, Krystal M, Enami M, Parvin JD, Palese P (1989) Amplification, expression, and packaging of foreign gene by influenza virus. Cell 59:1107–1113PubMedGoogle Scholar
  69. Lyles D, Rupprecht C (2007) Rhabdoviridae. In: Knipe D, Howley P (eds) Fields virology, vol 1. Lippincott, Williams, Wilkins, Philadelphia, pp 1363–1408Google Scholar
  70. Martin A, Staeheli P, Schneider U (2006) RNA polymerase II-controlled expression of antige-nomic RNA enhances the rescue efficacies of two different members of the Mononegavirales independently of the site of viral genome replication. J Virol 80:5708–5715PubMedGoogle Scholar
  71. Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, Blum P, Woodward S, McCarthy K, Mathis D, Johnson C, Bedford P (2003) Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immuno-genicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 188:1213–1230PubMedGoogle Scholar
  72. Mrkic B, Pavlovic J, Rulicke T, Volpe P, Buchholz CJ, Hourcade D, Atkinson JP, Aguzzi A, Cattaneo R (1998) Measles virus spread and pathogenesis in genetically modified mice. J Virol 72:7420–7427PubMedGoogle Scholar
  73. Naim HY, Ehler E, Billeter MA (2000) Measles virus matrix protein specifies apical virus release and glycoprotein sorting in epithelial cells. EMBO J 19:3576–3585PubMedGoogle Scholar
  74. Nakayama T, Komase K, Uzuka R, Hoshi A, Okafuji T (2001) Leucine at position 278 of the AIK-C measles virus vaccine strain fusion protein is responsible for reduced syncytium formation. J Gen Virol 82:2143–2150PubMedGoogle Scholar
  75. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, Hughes M, Perez DR, Donis R, Hoffmann E, Hobom G, Kawaoka Y (1999) Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A 96:9345–9350PubMedGoogle Scholar
  76. Palin A, Chattopadhyay A, Park S, Delmas G, Suresh R, Senina S, Perlin DS, Rose JK (2007) An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge. Vaccine 25:741–750PubMedGoogle Scholar
  77. Park KH, Huang T, Correia FF, Krystal M (1991) Rescue of a foreign gene by Sendai virus. Proc Natl Acad Sci U S A 88:5537–5541PubMedGoogle Scholar
  78. Parks CL, Lerch RA, Walpita P, Wang HP, Sidhu MS, Udem SA (2001a) Analysis of the noncod-ing regions of measles virus strains in the Edmonston vaccine lineage. J Virol 75:921–933Google Scholar
  79. Parks CL, Lerch RA, Walpita P, Wang HP, Sidhu MS, Udem SA (2001b) Comparison of predicted amino acid sequences of measles virus strains in the Edmonston vaccine lineage. J Virol 75:910–920Google Scholar
  80. Patterson JB, Cornu TI, Redwine J, Dales S, Lewicki H, Holz A, Thomas D, Billeter MA, Oldstone MB (2001) Evidence that the hypermutated M protein of a subacute sclerosing pan-encephalitis measles virus actively contributes to the chronic progressive CNS disease. Virology 291:215–225PubMedGoogle Scholar
  81. Peeters BP, de Leeuw OS, Koch G, Gielkens AL (1999) Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol 73:5001–5009PubMedGoogle Scholar
  82. Polo JM, Belli BA, Driver DA, Frolov I, Sherrill S, Hariharan MJ, Townsend K, Perri S, Mento SJ, Jolly DJ, Chang SM, Schlesinger S, Dubensky TW Jr (1999) Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. Proc Natl Acad Sci U S A 96:4598–4603PubMedGoogle Scholar
  83. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF (1997) Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239:389–401PubMedGoogle Scholar
  84. Racaniello VR, Baltimore D (1981) Cloned poliovirus complementary DNA is infectious in mammalian cells. Science 214:916–919PubMedGoogle Scholar
  85. Radecke F, Billeter MA (1996) The nonstructural C protein is not essential for multiplication of Edmonston B strain measles virus in cultured cells. Virology 217:418–421PubMedGoogle Scholar
  86. Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, Dotsch C, Christiansen G, Billeter MA (1995) Rescue of measles viruses from cloned DNA. EMBO J 14:5773–5784PubMedGoogle Scholar
  87. Rager M, Vongpunsawad S, Duprex WP, Cattaneo R (2002) Polyploid measles virus with hexam-eric genome length. EMBO J 21:2364–2372PubMedGoogle Scholar
  88. Roberts A, Rose JK (1999) Redesign and genetic dissection of the rhabdoviruses. Adv Virus Res 53:301–319PubMedGoogle Scholar
  89. Roberts A, Buonocore L, Price R, Forman J, Rose JK (1999) Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 73:3723–3732PubMedGoogle Scholar
  90. Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ, Donahoe SM, Montefiori D, Roberts A, Buonocore L, Rose JK (2001) An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106:539–549PubMedGoogle Scholar
  91. Ryan MD, Drew J (1994) Foot-and-mouth disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein. EMBO J 13:928–933PubMedGoogle Scholar
  92. Schmidt AC, McAuliffe JM, Huang A, Surman SR, Bailly JE, Elkins WR, Collins PL, Murphy BR, Skiadopoulos MH (2000) Bovine parainfluenza virus type 3 (BPIV3) fusion and hemag-glutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol 74:8922–8929PubMedGoogle Scholar
  93. Schmidt AC, Wenzke DR, McAuliffe JM, St Claire M, Elkins WR, Murphy BR, Collins PL (2002) Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J Virol 76:1089–1099PubMedGoogle Scholar
  94. Schneider H, Kaelin K, Billeter MA (1997) Recombinant measles viruses defective for RNA editing and V protein synthesis are viable in cultured cells. Virology 227:314–322PubMedGoogle Scholar
  95. Schnell MJ, Mebatsion T, Conzelmann KK (1994) Infectious rabies viruses from cloned cDNA. EMBO J 13:4195–4203PubMedGoogle Scholar
  96. Schnell MJ, Foley HD, Siler CA, McGettigan JP, Dietzschold B, Pomerantz RJ (2000) Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci U S A 97:3544–3549PubMedGoogle Scholar
  97. Schwartz JA, Buonocore L, Roberts A, Suguitan A Jr, Kobasa D, Kobinger G, Feldmann H, Subbarao K, Rose JK (2007) Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection. Virology 366:166–173PubMedGoogle Scholar
  98. Sidhu MS, Chan J, Kaelin K, Spielhofer P, Radecke F, Schneider H, Masurekar M, Dowling PC, Billeter MA, Udem SA (1995) Rescue of synthetic measles virus minireplicons: measles genomic termini direct efficient expression and propagation of a reporter gene. Virology 208:800–807PubMedGoogle Scholar
  99. Simon ID, Publicover J, Rose JK (2007) Replication and propagation of attenuated vesicular stomatitis virus vectors in vivo: vector spread correlates with induction of immune responses and persistence of genomic RNA. J Virol 81:2078–2082PubMedGoogle Scholar
  100. Singh M, Billeter MA (1999) A recombinant measles virus expressing biologically active human interleukin-12. J Gen Virol 80:101–106PubMedGoogle Scholar
  101. Singh M, Cattaneo R, Billeter MA (1999) A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J Virol 73:4823–4828PubMedGoogle Scholar
  102. Skiadopoulos MH, Surman SR, Riggs JM, Orvell C, Collins PL, Murphy BR (2002) Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins. Virology 297:136–152PubMedGoogle Scholar
  103. Skiadopoulos MH, Schmidt AC, Riggs JM, Surman SR, Elkins WR, St Claire M, Collins PL, Murphy BR (2003a) Determinants of the host range restriction of replication of bovine parain-fluenza virus type 3 in rhesus monkeys are polygenic. J Virol 77:1141–1148Google Scholar
  104. Skiadopoulos MH, Vogel L, Riggs JM, Surman SR, Collins PL, Murphy BR (2003b) The genome length of human parainfluenza virus type 2 follows the rule of six, and recombinant viruses recovered from non-polyhexameric-length antigenomic cDNAs contain a biased distribution of correcting mutations. J Virol 77:270–279Google Scholar
  105. Spielhofer P (1995) Generation of standard, variant and chimeric measles viruses from cloned DNA. PhD thesis, University of Zurich, Zurich, SwitzerlandGoogle Scholar
  106. Spielhofer P, Bachi T, Fehr T, Christiansen G, Cattaneo R, Kaelin K, Billeter MA, Naim HY (1998) Chimeric measles viruses with a foreign envelope. J Virol 72:2150–2159PubMedGoogle Scholar
  107. Springfeld C, von Messling V, Frenzke M, Ungerechts G, Buchholz CJ, Cattaneo R (2006) Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res 66:7694–7700PubMedGoogle Scholar
  108. Takeda M, Ohno S, Seki F, Nakatsu Y, Tahara M, Yanagi Y (2005) Long untranslated regions of the measles virus M and F genes control virus replication and cytopathogenicity. J Virol 79:14346–14354PubMedGoogle Scholar
  109. Takeda M, Nakatsu Y, Ohno S, Seki F, Tahara M, Hashiguchi T, Yanagi Y (2006) Generation of measles virus with a segmented RNA genome. J Virol 80:4242–4248PubMedGoogle Scholar
  110. Tangy F, Naim HY (2005) Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector. Viral Immunol 18:317–326PubMedGoogle Scholar
  111. Tani H, Komoda Y, Matsuo E, Suzuki K, Hamamoto I, Yamashita T, Moriishi K, Fujiyama K, Kanto T, Hayashi N, Owsianka A, Patel AH, Whitt MA, Matsuura Y (2007) Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins. J Virol 81:8601–8612PubMedGoogle Scholar
  112. Taniguchi T, Palmieri M, Weissmann C (1978) QB DNA-containing hybrid plasmids giving rise to QB phage formation in the bacterial host. Nature 274:223–228PubMedGoogle Scholar
  113. Tatsuo H, Ono N, Tanaka K, Yanagi Y (2000) SLAM (CDw150) is a cellular receptor for measles virus. Nature 406:893–897PubMedGoogle Scholar
  114. Tatsuo H, Ono N, Yanagi Y (2001) Morbilliviruses use signaling lymphocyte activation molecules (CD150) as cellular receptors. J Virol 75:5842–5850PubMedGoogle Scholar
  115. Tubulekas I, Berglund P, Fleeton M, Liljestrom P (1997) Alphavirus expression vectors and their use as recombinant vaccines: a minireview. Gene 190:191–195PubMedGoogle Scholar
  116. Ungerechts G, Springfeld C, Frenzke ME, Lampe J, Johnston PB, Parker WB, Sorscher EJ, Cattaneo R (2007a) Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res 67:10939–10947Google Scholar
  117. Ungerechts G, Springfeld C, Frenzke ME, Lampe J, Parker WB, Sorscher EJ, Cattaneo R (2007b) An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther 15:1991–1997Google Scholar
  118. Valsamakis A, Schneider H, Auwaerter PG, Kaneshima H, Billeter MA, Griffin DE (1998) Recombinant measles viruses with mutations in the C, V, or F gene have altered growth phe-notypes in vivo. J Virol 72:7754–7761PubMedGoogle Scholar
  119. Vigil A, Park MS, Martinez O, Chua MA, Xiao S, Cros JF, Martinez-Sobrido L, Woo SL, Garcia-Sastre A (2007) Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res 67:8285–8292PubMedGoogle Scholar
  120. von Messling V, Cattaneo R (2004) Toward novel vaccines and therapies based on negative-strand RNA viruses. Curr Topics Microbiol Immunol 283:281–312Google Scholar
  121. Wang Z, Hangartner L, Cornu TI, Martin LR, Zuniga A, Billeter MA, Naim HY (2001) Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses. Vaccine 19:2329–2336PubMedGoogle Scholar
  122. Wertz GW, Perepelitsa VP, Ball LA (1998) Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus. Proc Natl Acad Sci U S A 95:3501–3506PubMedGoogle Scholar
  123. Whelan SP, Ball LA, Barr JN, Wertz GT (1995) Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Natl Acad Sci U S A 92:8388–8392PubMedGoogle Scholar
  124. Zuniga A, Wang Z, Liniger M, Hangartner L, Caballero M, Pavlovic J, Wild P, Viret JF, Glueck R, Billeter MA, Naim HY (2007) Attenuated measles virus as a vaccine vector. Vaccine 25:2974–2983Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  1. 1.University of ZurichZurichSwitzerland
  2. 2.Berna BiotechBerneSwitzerland
  3. 3.Consultant for Internatl. AIDS Vaccine Initiative (IAVI)New YorkUSA

Personalised recommendations